statistiche ricercatore

Continente	#
NA - Nord America	1.202
AS - Asia	347
EU - Europa	285
SA - Sud America	77
Continente sconosciuto - Info sul continente non disponibili	71
AF - Africa	26
OC - Oceania	1
Totale	2.009

Nazione	#
US - Stati Uniti d'America	1.183
SG - Singapore	111
CN - Cina	105
BR - Brasile	67
IT - Italia	62
RU - Federazione Russa	53
SE - Svezia	49
HK - Hong Kong	44
VN - Vietnam	35
DE - Germania	32
GB - Regno Unito	25
FI - Finlandia	17
FR - Francia	17
CI - Costa d'Avorio	16
BD - Bangladesh	11
CA - Canada	11
BE - Belgio	9
IN - India	7
ID - Indonesia	6
EC - Ecuador	5
LT - Lituania	5
MX - Messico	5
IQ - Iraq	4
JP - Giappone	4
CO - Colombia	3
NL - Olanda	3
PH - Filippine	3
PL - Polonia	3
UA - Ucraina	3
UZ - Uzbekistan	3
AE - Emirati Arabi Uniti	2
ES - Italia	2
EU - Europa	2
JO - Giordania	2
KE - Kenya	2
PK - Pakistan	2
TN - Tunisia	2
TR - Turchia	2
ZA - Sudafrica	2
A2 - ???statistics.table.value.countryCode.A2???	1
AL - Albania	1
AO - Angola	1
AU - Australia	1
BG - Bulgaria	1
CL - Cile	1
DO - Repubblica Dominicana	1
DZ - Algeria	1
ET - Etiopia	1
IE - Irlanda	1
KG - Kirghizistan	1
LK - Sri Lanka	1
MK - Macedonia	1
MZ - Mozambico	1
NI - Nicaragua	1
OM - Oman	1
PS - Palestinian Territory	1
QA - Qatar	1
RO - Romania	1
SA - Arabia Saudita	1
VC - Saint Vincent e Grenadine	1
VE - Venezuela	1
Totale	1.941

Nome	#
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study	235
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta	190
A rare case of multiple sclerosis and McArdle disease	188
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort	187
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients	184
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients	171
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of Multiple Sclerosis	165
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy	163
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study	153
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis	152
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis.	151
null	65
Unusual anatomic variation: The posterior inferior cerebellar artery arising from the middle meningeal artery.	5
Totale	2.009

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	90	0	0	0	0	6	15	4	3	10	12	20	20
2022/2023	175	29	32	13	18	15	13	2	20	18	2	5	8
2023/2024	49	6	13	4	3	6	5	0	2	0	1	0	9
2024/2025	256	18	4	23	12	10	20	29	25	14	11	27	63
2025/2026	555	93	28	43	68	75	32	34	18	59	48	16	41
2026/2027	73	40	19	14	0	0	0	0	0	0	0	0	0
Totale													2.009